These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 10730885

  • 1. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
    Rössner P, Bubeník J, Sobota V, Indrová M, Hájková R, Mendoza L, Jandlová T, Símová J.
    Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
    [Abstract] [Full Text] [Related]

  • 2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R, Indrová M, Símová J, Jandlová T, Bieblová J, Jinoch P, Bubeník J, Vonka V.
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
    Hájková R, Indrová M, Jandlová T, Bubeník J, Reinis M.
    Folia Biol (Praha); 1999 Jan; 45(6):227-31. PubMed ID: 10732718
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J, Wu JH, Bouganim N, Galipeau J.
    Cancer Res; 2004 Dec 15; 64(24):8795-9. PubMed ID: 15604233
    [Abstract] [Full Text] [Related]

  • 5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N.
    J Immunother; 2001 Nov 01; 24(3):205-11. PubMed ID: 11394497
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
    Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC.
    Cancer Res; 1996 May 01; 56(9):2191-8. PubMed ID: 8616871
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.
    Cancer Res; 2000 Mar 15; 60(6):1663-70. PubMed ID: 10749137
    [Abstract] [Full Text] [Related]

  • 9. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
    Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H.
    Cancer Res; 1996 Apr 15; 56(8):1828-33. PubMed ID: 8620500
    [Abstract] [Full Text] [Related]

  • 10. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH, Chen Y, Chang CJ, Tai KF, Lin SM, Hwang LH.
    Clin Cancer Res; 2005 Feb 15; 11(4):1639-49. PubMed ID: 15746069
    [Abstract] [Full Text] [Related]

  • 11. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM.
    Cancer Res; 2003 Jan 15; 63(2):394-9. PubMed ID: 12543793
    [Abstract] [Full Text] [Related]

  • 12. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
    Shi FS, Weber S, Gan J, Rakhmilevich AL, Mahvi DM.
    Cancer Gene Ther; 1999 Jan 15; 6(1):81-8. PubMed ID: 10078967
    [Abstract] [Full Text] [Related]

  • 13. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M, Bubeník J, Mikysková R, Mendoza L, Símová J, Bieblová J, Jandlová T, Jinoch P, Smahel M, Vonka V, Pajtasz-Piasecka E.
    Int J Oncol; 2003 Mar 15; 22(3):691-5. PubMed ID: 12579325
    [Abstract] [Full Text] [Related]

  • 14. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
    Withoff S, Glazenburg KL, van Veen ML, Kraak MM, Hospers GA, Störkel S, de Vries EG, Wilschut J, Daemen T.
    Gene Ther; 2001 Oct 15; 8(20):1515-23. PubMed ID: 11704811
    [Abstract] [Full Text] [Related]

  • 15. Gene therapy with tumor vaccine increases the survival of hepatoma-bearing mice.
    Chao Y, Shih YL, Cheng HJ, Wei SJ, Chi KH, Yeh SH, Lee SD, Yang WK.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct 15; 62(10):682-9. PubMed ID: 10533297
    [Abstract] [Full Text] [Related]

  • 16. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A, Aruga E, Chang AE.
    Cancer Res; 1997 Aug 01; 57(15):3230-7. PubMed ID: 9242454
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J, Souberbielle BE, Sheikh N, Morrow WJ, Scott-Taylor T, Vile R, Chong H, Dalgleish AG.
    Gene Ther; 1999 Aug 01; 6(8):1475-81. PubMed ID: 10467372
    [Abstract] [Full Text] [Related]

  • 18. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Soo Hoo W, Carlo DJ.
    Gene Ther; 2002 Oct 01; 9(19):1302-11. PubMed ID: 12224013
    [Abstract] [Full Text] [Related]

  • 19. Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors.
    Yoshida H, Tanabe M, Miyauchi M, Kawamura K, Takenaga K, Ohnuma N, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 1999 Oct 01; 6(5):395-401. PubMed ID: 10505849
    [Abstract] [Full Text] [Related]

  • 20. Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity.
    Nakazaki Y, Tani K, Lin ZT, Sumimoto H, Hibino H, Tanabe T, Wu MS, Izawa K, Hase H, Takahashi S, Tojo A, Azuma M, Hamada H, Mori S, Asano S.
    Gene Ther; 1998 Oct 01; 5(10):1355-62. PubMed ID: 9930341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.